

The Hippocratic Cancer Research Foundation has been supporting cutting-edge, innovative work at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The Lurie Cancer Center has a long-standing history as a leading institution in cancer research and patient care and is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 28 of the world’s leading cancer centers that develop the guidelines for the treatment of cancer in the US and the world. Ranked #9 in the country in the last US News and World report, it is one of the leading academic comprehensive cancer centers in the country.

The Lurie Cancer Center is a national leader in the development of new treatments for cancer. Over the last few years there have been *18 new cancer drug FDA approvals* involving work performed by Lurie Cancer Center clinical investigators. The support of the Hippocratic Cancer Research Foundation continues to champion exceptional research and plays an important role in its academic excellence.

It’s the vision of HCRF to empower researchers, inform the public, and heal cancer patients through financial augmentation of the national cancer research initiatives undertaken by Dr. Platanius and his world- class team. HCRF provides funding for "think outside the box" research at the Lurie Cancer Center to address the most urgent concerns in the fields of cancer biology and oncology in daring and innovative ways.

With the support of HCRF, significant progress and breakthroughs have been made in cancer research in several areas. These include:

Understanding how the immune system works and developing immune therapies for cancer. The HCRF has supported work that has identified new potential targets for cancer immunotherapy drugs, based on the novel concept of intracellular immune checkpoints in cancer developed by Lurie Cancer Center investigators.	Supported studies involving a unique “cancer kill code” discovered by investigators in the Lurie Cancer Center and using it for the development of new cancer treatments.
Identifying molecular “wires” within cancer cells that promote resistance to treatments. The identification of molecular circuits that can be potentially targeted for future cancer treatments.	Supported important COVID research that led to unique discoveries that may have relevance beyond COVID.
Identifying promising new drug targets for brain cancer.	Have supported translational bridges to bring information from the laboratory to clinical trials in brain tumors, epigenetics, ovarian cancer, and skin tumors.
Discovering new pathways in malignant melanoma, opening new treatment options.	Innovative clinical trials in gynecological tumors, leukemia, and lymphomas.
Launching innovative clinical trials for cancer, providing patients with new fighting chance against their cancer.	Innovative clinical trials in prostate cancer and breast cancer.

The accomplishments HCRF has made to fulfill its mission to provide funding to Lurie’s Northwestern Cancer Research Center, Dr. Plataniotis, and his team of exceptional scientists and researchers could not be realized without the help and support of our donors and sponsors throughout the years. With your generosity fueling the efforts of Dr. Plataniotis and his incredible team, our vision will continue to become a reality, and we will persevere towards conquering cancer. *Join us in the fight.*

With deep gratitude and appreciation,



Eleni Bousis
Chair, Founding Board
Hippocratic Cancer Research Foundation